Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.
Related Articles
FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma
The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.
Frontiers | Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
Immune checkpoint blockers (ICB) bring unprecedented clinical success, yet many patients endure immune mediated adverse effects and/or fail to respond. Predi…
CKD Evaluation and Management – KDIGO
The guideline is intended for healthcare professionals who provide kidney care, for people with suspected or diagnosed CKD and their caregivers, and for policymakers and…
Figure 1. Healthcare administrator’s growth in the US. Healthcare…
Download scientific diagram | Healthcare administrator’s growth in the US. Healthcare administrator’s growth by 3200% between 1975 and 2010 compared to 150% Physician growth according…
Are Doctors Costing Hospitals $300K Per Year?
Report says doctors are ‘subsidized,’ but some question the math
22 pesticides show links to prostate cancer
The new finding comes from an analysis of pesticide use and prostate cancer incidence in over 3,100 U.S. counties.
Journal of Neuroendocrinology | BSN Journal | Wiley Online Library
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for…
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs,…
Charity calls for prostate-cancer testing of high-risk men
Prostate Cancer Research acknowledges more accurate tests would be needed to justify screening all men.
Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer
Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.